A detailed history of Prelude Capital Management, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 5,566 shares of ABBV stock, worth $984,903. This represents 0.07% of its overall portfolio holdings.

Number of Shares
5,566
Previous 5,566 -0.0%
Holding current value
$984,903
Previous $1.1 Million -0.0%
% of portfolio
0.07%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$163.84 - $199.33 $911,933 - $1.11 Million
5,566 New
5,566 $1.1 Million
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $18,716 - $23,794
-136 Reduced 5.11%
2,526 $387,000
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $493,077 - $611,770
-3,736 Reduced 58.39%
2,662 $432,000
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $687,337 - $869,680
6,398 New
6,398 $866,000
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $2.52 Million - $2.87 Million
-23,730 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $2.5 Million - $2.78 Million
23,730 New
23,730 $2.67 Million
Q1 2021

May 17, 2021

SELL
$102.3 - $112.62 $192,324 - $211,725
-1,880 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$80.49 - $108.67 $825,102 - $1.11 Million
-10,251 Reduced 84.5%
1,880 $201,000
Q3 2020

Nov 16, 2020

SELL
$85.91 - $100.83 $1.26 Million - $1.48 Million
-14,652 Reduced 54.71%
12,131 $1.06 Million
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $1.22 Million - $1.44 Million
15,827 Added 144.46%
26,783 $2.16 Million
Q4 2018

Feb 14, 2019

BUY
$77.85 - $96.01 $852,924 - $1.05 Million
10,956 New
10,956 $1.01 Million
Q2 2018

Aug 14, 2018

SELL
$89.78 - $106.23 $31,063 - $36,755
-346 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$92.01 - $123.21 $602,113 - $806,286
-6,544 Reduced 94.98%
346 $33,000
Q4 2017

Feb 14, 2018

BUY
$89.56 - $98.21 $617,068 - $676,666
6,890
6,890 $666,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $313B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.